

Implications of the New Treatment Fund for AWTTC



AWTTC

All Wales Therapeutics
& Toxicology Centre

Claire Ganderton

All Wales Therapeutics and Toxicology Centre

November 2017

“New treatment fund, open for business” – says Health Secretary

The Welsh Government’s new treatment fund is “open for business” with £80 million being made available over the life of this government to speed up access to the very latest medicines – Health Secretary Vaughan Gething has announced today.

Tuesday 10 January 2017

A total of £12 million will be released to health boards with immediate effect, with a further £4 million being made available later. The fund will provide additional support of £16 million annually to help health boards in Wales speed up access to medicines recommended by the National Institute for Health and Care Excellence (NICE) and the All Wales Medicines Strategy Group (AWMSG).

Under the new system, all health boards in Wales will be required to make a NICE or AWMSG recommended medicine available no later than two months from the date the final guidance is published shortening the

► Sign up to our:
[Newsletter](#) | [Newsfeeds](#)

NEWS BY SEARCH



NEWS BY TOPIC

- [All topics](#)
- [Business and economy](#)
- [Culture, tourism and sport](#)
- [Education and skills](#)
- [Environment and countryside](#)
- [Finance](#)
- [First Minister](#)
- [Health and social services](#)
- [Housing and Regeneration](#)

RELATED

LINKS

- [New treatment fund](#)

TAGS

- [Health and social services](#)
- [10 January 2017](#)

New Treatment Fund

- Help ease financial pressure for introduction of new medicines in NHS Wales
- £80 million; £16m per year across all HBs/Trust
- Faster & consistent availability of new medicines
 - within 60 days of FAD/FED/AWMSG publication
 - subject to PAS/CAA/MAA in place



New Treatment Fund (cont'd)

- Considerable challenge to Health Boards/Trust
 - budget allocation
 - associated service delivery need
 - consider medicines management policies
- Early intelligence
- “Once for Wales”



AWTTC activities: overview

Horizon scanning

Monitoring

Forecasting

Informing service



Horizon scanning

'the systematic examination of potential threats, opportunities and likely future developments, including (but not restricted to) those at the margins of current thinking and planning.'



Medicines horizon scanning

- Identify new medicines in development
- Prepare for innovation e.g. ATMP
- Support managed entry of new medicines
- Assist associated financial planning



Why is horizon scanning important in Wales?

- For Health Boards/Trust
 - implementation of NICE/AWMSG advice
- For AWTTTC
 - informs advanced financial forecasting
 - facilitates timely appraisal of new medicines
- For Welsh Government
 - investigate opportunity and threat
 - policy planning



AWTTC horizon scanning: identifying medicines for appraisal

- Medicines tracked using horizon scanning sources
- Form A requested at CHMP positive
- Decision made whether meets AWMSG criteria for appraisal
- Early engagement → medicines appraised and AWMSG advice issued as close to licence as possible



AWTTC horizon scanning: for forecasting and planning

Medicines Horizon Scanning and
Forecasting Group

AWTTC horizon scanning team



Medicines Horizon Scanning & Forecasting Group (MHSFG)

- To advise, inform and review the actions of AWTTC within the realm of this group
- To agree the list of medicines considered to have a significant financial or service delivery implication for NHS Wales.
- Facilitate communication between AWTTC and appropriate clinical experts to inform on potential NHS Wales uptake of specific medicines.
- To provide feedback on group output to the All Wales Joint Pharmacy and Finance Group.



AWTTC Medicines Horizon Scanning & Forecasting

- Identify new medicines likely to be launched within a 12 to 18 month horizon.
- Facilitate identification of a subset of these medicines
 - with a **high budget impact** and/or
 - have **significant implications for service delivery** e.g. ATMP
- Estimate potential budgetary implications of new medicines
- Disseminate forecasting information
- Progress electronic database hosting



AWTTC horizon scanning team

- Working on 2018 and 2019 medicines – per MHSFG
 - Horizon scanning sources, e.g. UK PharmaScan
 - Input from clinical experts
 - MHSFG
 - Industry
- Liaison with SMC
- AWTTC “vault” to share confidential information securely



Link to horizon scanning source http://www.ukmi.nhs.uk/applications/ndo/record_view.asp?newDrugID=4742

Pharmascan ID Current EU stage Pre-registration (Filed) Regulatory procedure

Comparators suggested on pharascan

Estimated MA filing
Estimated licence date
Estimated UK launch 01/10/2013
No plans for UK launch

Horizon Scanning reports

Q1: 01/01 Q2: 01/04 Q3: 01/07 Q4: 01/10 Q unknown: 31/01

Search by pharascan ID:

Drug Cost Upper est (per patient per year):

Estimated eligible patient population:

Estimated Budget Impact (Lower limit):

Drug Cost Lower est (per patient per year):

Eligible population classification:

Estimated Budget Impact (Upper limit):

Drug Cost Classification:

Budget Impact classification:

Service Impact:

Sources:

Horizon Scanning Query

Cost Information:

Horizon scanning directory:

AWTTC horizon scanning: moving forward

- Reports for service and WG
- Review AWTTC process
- Clinical experts
 - Identification
 - Engagement
- Work closely with the service via MHSFG
- Increased intelligence from NICE
- Encouraging AN submission via secure portal (where info not available elsewhere, e.g. on UK PharmaScan)






Some challenges

- Horizon scanning allows early identification of new medicines, however:
 - Medicine may not get a marketing authorisation
 - The licensed and appraised indications may be different
 - The medicine may not be recommended by NICE/AWMSG
 - Patient numbers difficult to predict
 - Identifying treatment pathways
 - Cost data difficult to obtain
 - PAS prices and issues with confidentiality
 - Identifying industry contacts
 - Identifying appropriate experts within Wales



Collaboration



Thank you Diolch yn fawr



AWTTC
All Wales Therapeutics
& Toxicology Centre

www.awttc.org

All Wales Therapeutics and Toxicology Centre
Academic Building
University Hospital Llandough
Penlan Road
Penarth
Vale of Glamorgan
CF64 2XX



PAMS
Patient Access to
Medicines Service



WeMeReC
Welsh Medicines
Resource Centre



WAPSU
Welsh Analytical
Prescribing Support Unit



WNPU
Welsh National
Poisons Unit



Yellowcard
Centre
Wales